News
XOMA
24.20
-1.31%
-0.32
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
NASDAQ · 22h ago
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
NASDAQ · 1d ago
Weekly Report: what happened at XOMA last week (0429-0503)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
TipRanks · 05/01 10:17
Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women's health assets. Bayer HealthCare holds the exclusive rights to U.S. Commercialization of Ovaprene.
Benzinga · 04/30 11:36
XOMA CORP: ENTITLED TO POTENTIAL MILESTONE PAYMENTS BASED ON COMMERCIAL SUCCESS OF XACIATO
Reuters · 04/30 11:32
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023. XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women's health assets. Sildenafil Cream is a potential candidate for female sexual arousal disorder.
Barchart · 04/30 06:30
Cracking The Code: Understanding Analyst Reviews For XOMA
4 analysts have expressed a variety of opinions on XOMA (NASDAQ:XOMA) over the past quarter. The average price target is $65.5, with a 12-month price target of $74.00. The company is a biotechnology royalty aggregator. Analysts have recently evaluated XOMa and provided price targets for the company.
Benzinga · 04/29 14:00
XOMA Price Target Announced at $40.00/Share by Leerink Partners
Dow Jones · 04/29 13:04
Weekly Report: what happened at XOMA last week (0422-0426)?
Weekly Report · 04/29 12:02
XOMA CORP <XOMA.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $40
Reuters · 04/29 10:16
XOMA Price Target Maintained With a $74.00/Share by HC Wainwright & Co.
Dow Jones · 04/25 11:33
XOMA EARNS $9 MILLION MILESTONE AS FDA GRANTS ACCELERATED APPROVAL TO DAY ONE’S OJEMDATM (TOVORAFENIB) FOR RELAPSED OR REFRACTORY BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Reuters · 04/25 11:30
HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
Benzinga · 04/25 11:23
*Correct: Actym Therapeutics, Not AnaptysBio, Appoints Thomas Smart as CEO
Dow Jones · 04/24 13:08
*AnaptysBio Names Thomas Smart as CEO >ANAB
Dow Jones · 04/24 13:01
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO of a new drug modality to treat solid tumors. Mr. Smart has 25 years of experience in senior management and executive roles across the biopharmaceutical industry. Actym's lead candidate, ACTM-838, will enter clinical evaluation later this year.
Dow Jones · 04/24 13:00
Day One wins FDA nod brain cancer therapy, Ojemda
Day One Biopharmaceuticals’ lead candidate tovorafenib for a type of pediatric brain cancer called low-grade glioma. The treatment branded as Ojemda will be indicated in the U.S. For children with relapsed or refractory pediatric gliomas. XOMA (NASDAQ:XOMA) received a $5M milestone payment after the decision.
Seeking Alpha · 04/23 17:59
Weekly Report: what happened at XOMA last week (0415-0419)?
Weekly Report · 04/22 11:49
Weekly Report: what happened at XOMA last week (0408-0412)?
Weekly Report · 04/15 11:40
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about Xoma Corp Del through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).